The Vascular Niche for Adult Cardiac Progenitor Cells.

Data de publicació: 29/04/2022 Data Ahead of Print: 29/04/2022

Autors de IIS La Fe

Pilar Sepúlveda Sanchis

Autor

Autors aliens a IIS La Fe

Herrero, Diego
Albericio, Guillermo
Higuera, Marina
Herranz-Lopez, Maria
Garcia-Brenes, Miguel A
Cordero, Alejandra
Roche, Enrique
Mora, Carmen
Bernad, Antonio

Grups d'Investigació

Regeneración y Trasplante Cardíaco

Leader

Pilar Sepúlveda Sanchis

Abstract

Research on cardiac progenitor cell populations has generated expectations about their potential for cardiac regeneration capacity after acute myocardial infarction and during physiological aging; however, the endogenous capacity of the adult mammalian heart is limited. The modest efficacy of exogenous cell-based treatments can guide the development of new approaches that, alone or in combination, can be applied to boost clinical efficacy. The identification and manipulation of the adult stem cell environment, termed niche, will be critical for providing new evidence on adult stem cell populations and improving stem-cell-based therapies. Here, we review and discuss the state of our understanding of the interaction of adult cardiac progenitor cells with other cardiac cell populations, with a focus on the description of the B-CPC progenitor population (Bmi1+ cardiac progenitor cell), which is a strong candidate progenitor for all main cardiac cell lineages, both in the steady state and after cardiac damage. The set of all interactions should be able to define the vascular cardiac stem cell niche, which is associated with low oxidative stress domains in vasculature, and whose manipulation would offer new hope in the cardiac regeneration field.

Dades de la publicació

ISSN/ISSNe:: 2076-3921, 2076-3921
Tipus:: Article
Pàgines:: -
DOI:: 10.3390/antiox11050882
PubMed:: 35624750
Factor d'Impacte:: 1,008 SCImago ℠
Quartil:: Q1 SCImago ℠

Documents

No hi ha documents

Mètriques

Filiacions

Herrero, Diego:: 1Department of Immunology & Oncology, National Center for Biotechnology (CNB-CSIC), Campus de Cantoblanco de la Universidad Autónoma de Madrid, 28049 Madrid, Spain., España.
Albericio, Guillermo:: 1Department of Immunology & Oncology, National Center for Biotechnology (CNB-CSIC), Campus de Cantoblanco de la Universidad Autónoma de Madrid, 28049 Madrid, Spain., España.
Higuera, Marina:: 1Department of Immunology & Oncology, National Center for Biotechnology (CNB-CSIC), Campus de Cantoblanco de la Universidad Autónoma de Madrid, 28049 Madrid, Spain., España.
Herranz-Lopez, Maria:: 1Department of Immunology & Oncology, National Center for Biotechnology (CNB-CSIC), Campus de Cantoblanco de la Universidad Autónoma de Madrid, 28049 Madrid, Spain., España.
Garcia-Brenes, Miguel A:: 1Department of Immunology & Oncology, National Center for Biotechnology (CNB-CSIC), Campus de Cantoblanco de la Universidad Autónoma de Madrid, 28049 Madrid, Spain., España.
Cordero, Alejandra:: 1Department of Immunology & Oncology, National Center for Biotechnology (CNB-CSIC), Campus de Cantoblanco de la Universidad Autónoma de Madrid, 28049 Madrid, Spain., España.
Roche, Enrique:: 3 Institute of Bioengineering and Department of Applied Biology-Nutrition, Miguel Hernández University, 03202 Elche, Spain., España.

4Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), 03010 Alicante, Spain., España.
Sepulveda, Pilar:: Instituto de Investigación. 5 Regenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, Avda, Fernando Abril Martorell 106, 46026 Valencia, Spain. PMID: 35624750 PMCID: PMC9137669 DOI: 10.3390/antiox11050882, España.
Mora, Carmen:: 1Department of Immunology & Oncology, National Center for Biotechnology (CNB-CSIC), Campus de Cantoblanco de la Universidad Autónoma de Madrid, 28049 Madrid, Spain., España.
Bernad, Antonio:: 1Department of Immunology & Oncology, National Center for Biotechnology (CNB-CSIC), Campus de Cantoblanco de la Universidad Autónoma de Madrid, 28049 Madrid, Spain., España.